deltatrials
Completed PHASE3 NCT00748098

Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance

Study RXP110908, a Polysomnography Study of GSK1838262 (XP13512) Extended Release Tablets Versus Placebo in the Treatment of Restless Legs Syndrome (RLS) and Associated Sleep Disturbance

Sponsor: XenoPort, Inc.

Conditions Restless Legs Syndrome Restless Legs Syndrome (RLS)
Interventions GSK1838262 Extended Release Tablets Placebo
Updated 7 times since 2017 Last updated: Jul 15, 2013 Started: Oct 31, 2008 Primary completion: Jul 31, 2009 Completion: Jul 31, 2009

This PHASE3 trial investigates Restless Legs Syndrome and Restless Legs Syndrome (RLS) and is currently completed. XenoPort, Inc. leads this study, which shows 7 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • XenoPort, Inc.
Data source: XenoPort, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States, Austin, United States, Baltimore, United States, Brighton, United States, Chevy Chase, United States, Cincinnati, United States, Cleveland, United States, Columbia, United States, Crestview Hills, United States, Dublin, United States and 13 more location s